Research
Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study
Cite this as:
BMJ
2012;345:e7086
- Our online table of contents is updated at least twice each day. Read all articles published in the last 7 days.
- You can use bmj.com to help you with your continuing medical education. Find out about CME/CPD credits for BMJ articles
- Keep up to date with cardiology: Access the latest cardiovascular medicine resources from across BMJ Group.
-
OPEN ACCESS: All research articles are freely available online, with no word limit. Find out more about the BMJ's open access policy. Submit your paper. - Find out how study types differ in our How to read a paper section.
Recent rapid responses
Rapid responses are electronic letters to the editor. They enable our users to debate issues raised in articles published on bmj.com. Although a selection of rapid responses will be included as edited readers' letters in the weekly print issue of the BMJ, their first appearance online means that they are published articles. If you need the url (web address) of an individual response, perhaps for citation purposes, simply click on the response headline and copy the url from the browser window.
Displaying 1-2 out of 2 published
5 November 2012
As an afterthought of my previous response to the same article, I suggest once the woman has become HPV negative, she should be immunized with HPV vaccine to acquire lifelong immunity against oncogenic strains (6, 11, 16 & 18). There is a possibility of subsequent re-infection by HPV after cure if the patient is not vaccinated(1) as in the case of Diphtheria where the disease does not give lifelong immunity and one has to be given a full course of immunization.
1. http://www.parentingbanter.com/showthread.php?t=66758
Competing interests: None declared
Indian Council of Medical Research, Ansari Nagar, New Delhi-11029
Click to like:
47
+Vote up!
3 November 2012
The post-treatment follow-up will not be helped by HPV DNA’s detection only once at six-months (declaring as cure) and thereafter calling the patient as routine recalls just as for the population at risk1. Following facts should as well be considered:
1. Human Papilloma virus infection may recur and become as risky again in spite of a negative result at six month’s follow-up.
2. The previous cervical dysplasia has a recurrence of four-fold as stated in other, just published paper in BMJ2. It may be due to high risk behavior and reduced immunity.
Since it is clear that the cancer or its cause (HPV) may recur, so cost-effectiveness study is not commensurate with biological explanation. And the patient may need the three repeat cytology tests at six, 12, and 24 months and thereafter annual follow-ups as the usual practice till now.
References:
1. BMJ 2012;345:e7086
2. BMJ 2012;345:e6855
Competing interests: None declared
Indian Council of Medical Reserch, Ansari Nagar, New Delhi-110029
Click to like:
57
+Vote up!
Latest comments and most commented
Re: War of the words
Published 22 May 2013
Re: Better management of patients with multimorbidity
Published 22 May 2013
Re: John Hayward
Published 22 May 2013
Smoking cessation is a priority in psychiatric patients
Published 22 May 2013